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Objectives: To assess the mortality in patients with diabetes mellitus (DM) following per-
cutaneous coronary intervention (PCI) according to their insulin requirement and PCI
setting (elective, urgent, and emergency). Background: DM is a major risk factor to
develop coronary artery disease (CAD). It is unclear if meticulous glycemic control and
aggressive risk factor management in patients with DM has improved outcomes fol-
lowing PCI. Methods: Retrospective analysis of prospectively collected data on 9,224
patients treated with PCI at a regional tertiary center between 2008 and 2011. Results:
About 7,652 patients were nondiabetics (non-DM), 1,116 had non-insulin treated diabe-
tes mellitus (NITDM) and 456 had ITDM. Multi-vessel coronary artery disease, renal
impairment and non-coronary vascular disease were more prevalent in DM patients.
Overall 30-day mortality rate was 2.4%. In a logistic regression model, the adjusted
odds ratios (95% confidence intervals [CI]) for 30-day mortality were 1.28 (0.81–2.03,
P5 0.34) in NITDM and 2.82 (1.61–4.94, P< 0.001) in ITDM compared with non-DM. Dur-
ing a median follow-up period of 641 days, longer-term post-30 day mortality rate was
5.3%. In the Cox’s proportional hazard model, the hazard ratios (95% CI) for longer-
term mortality were 1.15 (0.88–1.49, P5 0.31) in NITDM and 1.88 (1.38–2.55, P<0.001) in
ITDM compared with non-DM group. Similar result was observed in all three different
PCI settings. Conclusion: In the modern era of aggressive cardiovascular risk factor
control in diabetes, this study reveals higher mortality only in insulin-treated diabetic
patients following PCI for stable coronary artery disease and acute coronary syn-
drome. Importantly, diabetic patients with good risk factor control and managed on
diet or oral hypoglycemics have similar outcomes to the non-diabetic population. VC
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INTRODUCTION
Diabetes mellitus (DM) is a multisystem disorder
and a recognized risk factor for coronary artery disease
(CAD). CAD accounts for most deaths in patients with
DM [1,2], although the higher mortality in diabetic
patients has been shown to be independent of their
documented CAD status [3].
Aggressive cardiovascular risk factor control in
patients with diabetes mellitus is standard practice and
recommended by all current guidelines [4]. Although,
contemporary population data demonstrates evidence
of reduction in cardiovascular complications with risk
factor control in patients with diabetes [5,6], it is not
known whether this translates to improvements follow-
ing coronary revascularization as recent randomized
control trials continue to show worst outcomes in dia-
betic patients with complex coronary artery disease
when treated with PCI compared with coronary artery
bypass graft (CABG) [7–9].
Outcome data in non-selected “real world” diabetic
patients treated with PCI in the modern era of aggres-
sive secondary prevention, drug-eluting stents and new
anti-platelet therapy remains scarce.
The aim of this study was to assess mortality out-
comes following PCI in patients with a known prior
history of diabetes treatment and compare against mor-
tality in the non-diabetic population. A secondary
objective was to assess mortality in these populations
stratified according to the different clinical setting—
stable, non-ST elevation acute coronary syndrome
(NSTE-ACS) and ST elevation myocardial infarction
(STEMI).
METHODS
Study Population
The study population consisted of all patients under-
going PCI between March 2008 and December 2011 at
Freeman Hospital, Newcastle-upon-Tyne, UK—a tertia-
ry center in the northeast of England, performing
approximately 3,000 PCI a year, delivered by 10 inter-
ventional cardiologists.
Study Design
This is a retrospective analysis of prospectively col-
lected data on all PCI patients. The primary source of
data was our local Coronary Artery Disease (CAD)
database (Dendrite), which holds information on every
PCI procedure performed at our hospital. Baseline
demographics, clinical presentation, procedure details
were prospectively entered into the database with
clinical data and medications updated on discharge.
Outcome Measures
The main outcome measure was all-cause mortality
assessed at 30 days post index PCI procedure (30-day
mortality) and between 30 days post PCI and long term
follow-up (longer-term mortality). Mortality data were
provided by the Office of National Statistics (ONS) and
linked to our database using National Health Service
(NHS) patient-unique identification numbers (NHS
numbers), which was further confirmed by patients’ birth
date and home address. Mortality was assessed up to the
2nd February 2012, and patient follow-up was censored
upon death.
Diabetes and Procedure Status
Patients were categorized into three groups: non-
diabetes mellitus (non-DM) group, non-insulin treated
DM (non-ITDM) group, and insulin treated DM (ITDM)
group. Diagnosis of diabetes mellitus was based on a
history of diabetes on admission.
PCI was classified according to the clinical setting:
“elective” PCI for patients presenting with stable CAD,
“urgent” PCI for patients with non-ST elevation acute
coronary syndrome (NST-ACS), and “primary” PCI
for patients with ST elevation myocardial infarction
(STEMI). The diagnosis of NST-ACS was based on hospi-
tal admission with unstable symptoms of cardiac ischemia
with or without ECG changes and/or raised biomarkers of
cardiac necrosis [10]. The diagnosis of STEMI was based
on the presence of chest pain suggestive of myocardial
ischemia greater than 30min, time of onset of symptoms
within 12 hr and new ST-segment elevation or left bundle
branch block (LBBB) on the electrocardiogram (ECG)
[11]. Tables I and IV provide additional data on admission
glucose and total cholesterol levels. PCI procedure and
diabetes status, and stent types used.
Patients with complex and multi-vessel coronary
artery disease or left main stem stenosis were dis-
cussed with the heart team unless presenting acutely
with hemodynamic instability and emergency PCI was
deemed necessary. Departmental policy with respect
to drug-eluting stents (DES) was to use in all patients
without contraindication to 12 months of dual anti-
platelet therapy such as high bleeding risk (requiring
or on prior anticoagulation, history of gastrointestinal
or other bleeding, need for surgery within 12 months
of the index PCI) or where a DES could not be
delivered.
Data are presented as percentages for categorical varia-
bles and as means6 standard deviations (SD) or medians
and interquartile ranges (25th to 75th) for continuous vari-
ables. Comparisons between groups were made using chi-
square test for categorical variables and one-way ANOVA
for continuous variables. Multiple logistic regression
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analysis was used to test for the impact of diabetes status
on 30-day mortality and correct for the following con-
founders: age, gender, previous myocardial infarction
(MI), multi-vessel coronary artery disease (MVD),
peripheral vascular disease (PVD), previous revascular-
ization, cardiogenic shock (in the urgent and primary
PCI settings), admission hemoglobin, creatinine, and
diabetes status. For the longitudinal analysis for longer-
term mortality, Kaplan–Meier survival curves were
generated and the log-rank test used to assess differ-
ences in survival. Cox proportional hazards regression
was used to assess the impact of diabetes groups on
longer-term mortality following adjustment for the
above mentioned confounders.
A P value <0.05 (2-sided) was considered statistically
significant. All analysis was performed using SPSS (SPSS
version 19, SPSS, Inc., Chicago).
RESULTS
Study Groups and Baseline and Procedure
Characteristics
A total of 9,313 patients underwent PCI during study
period. Eighty-nine patients were excluded, as their dia-
betic status was not documented. Of the remaining 9,224
patients, 7,652 patients (83.09%) were non-DM, 1116
patients (12.1%) were NITDM, and 456 patients (4.9%)
ITDM.
Baseline characteristics of patients according to dia-
betic status are shown in Table V. Non-DM group were
youngest and the percentage of female gender was high-
est in the ITDM group compared with other groups. Both
diabetic groups had higher rates of patients with docu-
mented history of hypertension, hypercholesterolemia,
myocardial infarction (MI), cerebrovascular disease
(CVA), peripheral vascular disease (PVD), and previous
cardiac revascularization compared with non-DM group.
Table V also shows procedure related characteristics
in different groups. Rates of multi-vessel CAD, left main
stem stenosis and multi-vessel PCI were highest in
patients with diabetes with the highest rates seen in
ITDM group. There was a trend toward a higher usage of
DESs in ITDM compared with other groups (P5 0.059).
Cardiogenic shock rate was highest in ITDM group in
the urgent PCI setting but highest in NITDM group in the
primary PCI setting.
Procedure Settings
Elective PCI was performed in 2,916 patients (31.6%),
urgent PCI in 3,346 patients (36.3%) and primary PCI in
2,962 patients (32.1%). The non-DM group had the low-
est rate of elective PCI (30.1% compared with 39.5% in
NITDM group and 37.5% in ITDM group) but the high-
est rate of primary PCI (34.4% compared with 22% in
NITDM group and 19% ITDM group).
In-Stent Restenosis and in-Stent Thrombosis
Repeat revascularization for in-stent restenosis was
highest in ITDM group (4.4% compared with 1.5%
TABLE I. Admission Serum Glucose and Total Cholesterol Levels for Different Groups According to PCI Settings
Non-DM NITDM ITDM
Glucose: mmol/L (all) mg/dL 6.77 (2.51) 121.9 (45.2) 10.04 (4.48) 180.7 (80.6) 11.09 (5.56) 199.6 (100.1)
Elective PCI 5.83(2.60) 104.9 (46.8) 9.23 (3.65) 166.1 (3.65) 10.54 (5.10) 189.7 (91.8)
Urgent PCI 6.22 (1.61) 112.0 (29) 9.03 (3.74) 162.5 (67.3) 10.69 (5.20) 192.4 (90.4)
Emergency PCI 8.05 (2.56) 144.5 (46.1) 12.95 (5.45) 233.1 (98.1 12.85 (6.61) 231.3 (119)
Cholesterol; mmol/L (all) mg/dL 4.69 (1.31) 181.36 (50.65) 4.11 (1.19) 158.93 (46.01) 4.09 (1.36) 159.15 (52.59)
Elective PCI 4.02 (1.39) 155.45 (53.75) 3.98 (1.03) 153.90 (39.82) 4.01 (1.05) 155.06 (40.60)
Urgent PCI 4.69 (1.37) 181.36 (52.97) 4.12 (1.24) 159.31 (47.95) 4.07 (1.63) 157.38 (64.67)
Emergency PCI 5.05 (1.34) 195.28 (51.81) 4.33 (1.34) 167.44 (51.81) 4.28 (1.36) 165.50 (52.59)
Values expressed as mean (SD).
TABLE II. Actual Number and Percentages of PCI Settings in
Different Groups
Non-DM NITDM ITDM
Elective PCI 2304 (30.1%) 441 (39.5%) 171 (37.5%)
Urgent PCI 2719 (35.5%) 429 (38.4%) 198 (43.4%)
Emergency PCI 2629 (34.4%) 246 (22.0%) 87 (19.1%)
TABLE III. Percentages of the Number of Stents Used Per
Procedure in Each Group
Non-DM NITDM ITDM P
1 stent 46.8% 41.3% 42.8% 0.001
2–3 stents 36.8% 39.1% 33.1% 0.078
>3 stents 6.5% 4.7% 9.8% <0.001
TABLE IV. Type of Drug Eluting Stents as Percentages of
Total PCI Procedures
Non-DM NITDM ITDM
Cypher 10.9% 10.8% 12.3%
Taxus 1.0% 1.2% 1.8%
Endeavor 10.1% 9.1% 10.5%
Xience 29.6% 27.1% 33.3%
Integrity 5.4% 6.6% 5.0%
Promus 11.0% 12.3% 11.6%
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non-DM group and 1.8% NITDM group, P< 0.001). In
addition, angiographically confirmed in-stent thrombo-
sis was also highest in ITDM group (1.5% compared
with 0.5% in non-DM group and 0.3% in NITDM
group, P5 0.031).
Mortality Outcomes
The 30-day mortality. Overall 30-day mortality
rate was 2.4%. The respective figures following elective,
urgent, and primary PCI were 0.14%, 1.7%, and 5.3%.
Figure 1a shows 30-day mortality rates in different
groups and according to procedure settings.
In a logistic regression model adjusted for several
confounders, only the ITDM patients were associated
with an increased 30-day mortality compared with non-
DM, Fig. 1b. The above analysis was not performed in
the elective setting due to the very low 30-day low
mortality rates in all groups following elective PCI
(0.14% overall, 0.17% in non-DM, 0.01% in NITDM,
TABLE V. Demographics and Clinical Characteristics of Groups (Non-Diabetes Mellitus [non-DM], Non-Insulin Treated DM
[NITDM], and Insulin Treated DM [ITDM])
Non-DM NITDM ITDM P
Age, years 64.06 12.4 66.46 11.4 66.66 11.2 <0.001
Female, % 28.0 28.7 34.4 0.005
Bloods:
Hemoglobin, g/dL 13.96 2.4 13.46 1.9 12.96 1.9 <0.001
Creatinine, mmol/L 97.66 42.6 103.56 51.6 133.36 99.4 <0.001
Glucose, mmol/L 6.86 2.5 10.06 4.5 11.16 5.6 <0.001
Cholesterol, mmol/L 4.76 1.3 4.16 1.2 4.16 1.4 <0.001
Risk factors:
Hypertension, % 48.8 72.8 74.3 <0.001
Hypercholesterolemia, % 31.7 45.4 50.7 <0.001
Family history, % 53.1 55.9 51.3 0.90
Current smoking, % 30.8 20.6 20.1 <0.001
Ex-smoking, % 39.7 51.5 47.1 <0.001
BMI, kg/m2 27.76 4.9 30.56 5.2 31.76 7.3 <0.001
Past history:
Angina, % 36.1 55.8 65.8 <0.001
MI, % 22.5 35.9 48.0 <0.001
CABG, % 4.9 11.0 13.7 <0.001
Previous PCI, % 10.7 17.4 23.8 <0.001
CVA/TIA, % 5.2 8.3 12.3 0.001
PVD, % 4.3 7.9 14.7 <0.001
Airways disease, % 12.2 16.0 17.8 <0.001
Impaired LVSF,a % 41.4 42.4 49.0 <0.001
Procedure:
Radial, % 69.6 67.7 66.8 0.061
LMS stenosis, % 4.4 7.7 8.8 <0.001
Multi-vessel CAD, % 37.4 48.8 55.1 <0.001
Multi-vessel PCI, % 22.1 26.3 27.9 <0.001
Stent use (all), % 90.6 85.5 86.3 <0.001
DES, % 67.3 67.5 72.0 0.059
Cardiogenic shock, %
Urgent PCI 1.0 1.5 3.4 0.003
Primary PCI 4.5 8.0 3.2 0.014
Discharge drugsb:
Aspirin, % 96.4 96.6 97.2 0.71
Other antiplatelets, % 94.6 95.5 95.3 0.42
Statin, % 94.8 93.8 92.7 0.081
Beta Blocker, % 85.0 82.5 81.5 0.020
ACEi/ARB, % 85.1 84.3 81.7 0.14
Data are presented as mean6SD unless indicated otherwise.
Abbreviations: BMI, body mass index; MI, myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention;
CVA/TIA5 cerebrovascular accident/transient ischemic attack; PVD, peripheral vascular disease; LVSF, left ventricular systolic function; LMS, left
main stem; CAD, coronary artery disease; DES, drug-eluting stent; ACEi, angiotensin converting enzyme inhibitor, ARB, angiotensin receptor.
aLVSF data was available in 42.6%. Impaired LVSF is defined as LV ejection fraction <40%.
bDischarge medication data is available in 84.8%.
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and 0.01% in ITDM groups). Hosmer and Lemeshow
test was non-significant (P5 0.195).
Longer-term mortality. During a median (inter-
quartile range) follow-up period of 641 (319–984)
days, 695 patients (5.3%) died. Overall longer-term
mortality rates were 4.7% in the non-DM group, 6.8%
in NITDM, and 12.7% in ITDM group (P< 0.001).
Figure 2a shows longer-term mortality rates in groups
according to PCI settings. Figure 2b shows unadjusted
and adjusted hazard ratios for longer term mortality in
NITDM and ITDM groups compared with non-DM
group. In the Cox proportional hazard model, ITDM
was associated with increased longer-term mortality in
the overall cohort and in all PCI settings, whereas
NITDM was not associated with longer-term mortality
in any PCI setting.
Figure 3 compares the cumulative survival of the
non-DM, NITDM, and ITDM groups post 30-day
follow-up using Kaplan–Meier analysis.
DISCUSSION
This study of percutaneous coronary revasculariza-
tion in patients with a prior history of diabetes and
cardiovascular risk factor control reveals increased
mortality only in patients with diabetes mellitus requir-
ing insulin treatment but not in those on diet control or
oral hypoglycemic agents. When patients were assessed
on the basis of clinical presentation, this finding was
also evident both in the setting of stable coronary
artery disease and acute coronary syndrome. Of inter-
est, in the era of aggressive cardiovascular risk factor
control in patients with diabetes, those controlled on
diet or oral hypoglycemics had similar mortality to
non-diabetic patients following PCI, especially after
adjustment for differences in confounders.
Cardiovascular disease and its resulting complica-
tions account for the majority of deaths in patients
with diabetes mellitus [1,2]. However, recent popula-
tion studies confirm that aggressive risk factor control,
in particular lipids and blood pressure, have resulted in
reduction in coronary heart disease in the wider as well
Fig. 1. Thirty-day mortality rates. (a) Crude 30-day mortality
rates in different diabetes groups (non-diabetes mellitus [non-
DM], non-insulin treated DM [NITDM] and insulin treated DM
[ITDM]) following percutaneous coronary intervention (PCI) in
different settings; (b) unadjusted and adjusted odds ratios for
30-day mortality in NITDM and ITDM groups compared with
non-DM group. (a) Thirty-day mortality rates. (b) Odds ratios
for 30-day mortality.
Fig. 2. Longer-term mortality rates. (a) crude longer-term mor-
tality rates in different diabetes groups (non-diabetes mellitus
[non-DM], non-insulin treated DM [NITDM] and insulin treated
DM [ITDM]) following percutaneous coronary intervention (PCI)
in different settings; (b) unadjusted (un) and adjusted (ad) haz-
ard ratios for longer-term mortality in NITDM and ITDM groups
compared with non-DM group. (a) Longer-term mortality rates.
(b) Hazard ratios for longer-term mortality rates.
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as the diabetic population. Ford reported that compared
with a two years period (1999–2000), the estimated
10-year risk for developing coronary artery disease
among people with diagnosed diabetes was 22% lower
by 2007–2008 [5]. This improved risk factor control
may be one reason explaining the failure of more
aggressive hypoglycemic drugs to reduce macrovascu-
lar disease in diabetes [12,13]. Whether this improve-
ment in CHD as a result of risk factor control
translates to a reduction in mortality after revasculari-
zation has not previously been reported and our obser-
vational study provides data from a large cohort
suggesting this may be the case and provides stimulus
for further research. In addition to macro- and micro-
vascular disease, the Emerging Risk Factors Collabora-
tion study reported diabetes to be associated with
increased premature death from several cancers, infec-
tious diseases, intentional self-harm, and degenerative
disorders, independent of major risk factors [14]. This
large cohort study defined baseline diabetes status on
the basis of self-report, medication use, fasting glucose
level 126 mg/dL [7.0 mmol/L], or a combination of
these but did not differentiate mortality on the basis of
differences in management strategies. Our study did
not differentiate between the causes of death but
looked only at all-cause mortality in patients with
proven macrovascular disease.
The etiology of cardiovascular disease in diabetes
includes multiple factors involving an amalgamation of
maladaptive interactions, which promote inflammation,
increased oxidative stress, chronic activation of the
renin–angiotensin–aldosterone system, and abnormali-
ties of innate immunity [15,16]. These changes are
further compounded by alterations to the coagulation
system, which promote thrombosis through multiple
mechanisms and result in thrombus which is more
resistant to standard antithrombotic therapy. Our group
has previously reported increased thrombus burden in
patients with diabetes mellitus even when treated with
optimal secondary prevention therapies and dual anti-
platelet drugs [17] whilst others have also demonstrat-
ed higher platelet reactivity on dual antiplatelet therapy
[18]. In the setting of PCI, stent thrombosis is a cata-
strophic complication leading to death or myocardial
infarction and several studies report a strong associa-
tion with the presence of diabetes [19]. Subgroup
analyses in both The Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibi-
tion With Prasugrel-Thrombolysis in Myocardial
Infarction 38 (TRITON-TIMI 38) [20] and the PLATe-
let inhibition and patient Outcomes (PLATO) trial [21]
confirmed the beneficial role of more powerful anti-
platelet agents when compared with clopidogrel in the
diabetic arm but even so, this population had ischemic
outcomes that were approximately 20% higher than in
the non-diabetic population. Dual antiplatelet therapy is
not currently recommended in primary prevention in
patients with diabetes and, in secondary prevention, it
is only recommended for 12 months [22]. The effect of
dual antiplatelet therapy in this population is currently
Fig. 3. Kaplan–Meier survival curves for adjusted cumulative post-30 day longer-term mor-
tality in non-diabetes mellitus (non-DM), non-insulin treated DM (NITDM), and insulin-treated
DM (ITDM) groups. [Color figure can be viewed at wileyonlinelibrary.com]
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the subject of the THEMIS (Effect of Ticagrelor on
Health Outcomes in diabEtes Mellitus Patients Inter-
vention Study) which is a randomized clinical trial
looking at the effect of ticagrelor in addition to aspirin
in patients with type 2 diabetes mellitus and coronary
artery disease [23].
Our study also confirmed higher rates of both in-
stent restenosis and thrombosis in the insulin-treated
patients. Once again the mechanisms for the increased
in-stent complications are not known and our data pro-
vides supporting evidence for more focused studies in
patients with diabetes and macrovascular disease
treated with insulin.
The findings of the current study are consistent with
previous studies showing increased mortality in diabetic
patients with CAD following PCI [9,24,25]. However,
our findings are remarkable for revealing differential
mortality depending on insulin treatment and PCI set-
tings: increased mortality was only seen in those patients
requiring insulin for glycemic management. Compared
with the non-diabetic group, NITDM group showed simi-
lar mortality following elective, urgent and primary PCI,
especially after adjustment for confounding influences
such as higher rates of standard cardiovascular risk fac-
tors, comorbidities and multivessel disease. We can spec-
ulate that improved screening for cardiovascular risk
factors together with aggressive primary and secondary
prevention together, careful PCI case selection and a
relatively high usage of drug eluting stents may have
combined to bring mortality in NITDM to that seen in
the non-DM group.
There are several reasons why outcomes following
PCI may be less favorable in diabetic compared with
non-diabetic patients. Firstly, diabetic patients are more
likely to have comorbidities, such as PVD, hypertension,
renal impairment, and CVA [26,27] and our findings
support these observations. Secondly, the pattern of coro-
nary artery disease in diabetic patients is usually more
extensive and complex compared with non-diabetic
patients [28]. This is also evidence from our study of
higher rates of MVD in diabetic groups. Thirdly, even
following successful PCI, diabetes mellitus is associated
with higher rates of diffuse in-stent restenosis [29] as a
result of exuberant neointimal and smooth muscle cell
proliferation.
The reasons for the associated increased mortality spe-
cifically in insulin treated patients are unknown. Cardio-
vascular risk factors and comorbidities were highest in
ITDM group, which may have accounted, at least in part,
for their high mortality rates. Furthermore, studies of
insulin titration to blood glucose in patients presenting
with ST Elevation Myocardial Infarction have yielded
equivocal results and the optimal management of raised
blood glucose in the setting of ACS or stable CAD
remains contentious [30–32]. In fact, previous authors
have shown that insulin use may increase the risk of mor-
tality [33]. These findings allied to the risk of hypoglyce-
mia [34] and suggestions that insulin might promote
cardiovascular disease or cancers [35–37] have raised
concerns regarding the safety of insulin for type 2 diabe-
tes. However, conflicting evidence from an extended
follow-up of the trial with the biggest between-group dif-
ference in insulin use revealed a 15% reduction in myo-
cardial infarction and a 13% reduction in death among
people with new-onset type 2 diabetes [38]. The Out-
come Reduction with an Initial Glargine Intervention
(ORIGIN) trial [39] looked at the role of additional insu-
lin to normalize fasting blood glucose in patients with
diabetes mellitus. This relatively contemporary study
with a median follow up of 6.2 years in over 12,000
patients revealed a neutral effect on cardiovascular out-
comes and cancers but confirmed increased rates of
hypoglycemia and weight gain in insulin treated patients
both of which may adversely affect cardiovascular out-
comes over a more longer time period.
Guidelines from national bodies give strong recom-
mendation for insulin therapy in the acute phase follow-
ing myocardial infarction [4,40]. Our data is interesting
as it suggests that the chronic use of insulin is associated
with increased mortality although whether this is cause
and effect or simply that those requiring insulin represent
diabetes of longer duration and poorer control, as well as
having other underlying co-morbidities, cannot be deter-
mined from our study.
Diabetes is a multisystem disorder and in patients
with coronary artery disease, it amplifies ischemic
complications. Current treatment guidelines following
PCI (including duration of dual anti-platelet therapy
and secondary prevention) do not differentiate between
the diabetic, especially insulin-treated, and non-diabetic
populations. Furthermore, there is lack of trials specific
to this patient population with current data mainly
derived from subgroup analysis. There is early data
[41] to suggest that newer agents that inhibit inflamma-
tory state and immune response in atherosclerosis and
trials of these agents are awaited.
Published data in population studies confirm reduc-
tions in cardiovascular mortality in non-insulin treated
diabetic and non-diabetic patients following aggressive
risk factor control. Our data is interesting in showing
similar mortality after PCI in patients with non-insulin
treated diabetes and non-diabetic patients but increased
mortality only in diabetic patients requiring insulin
treatment. Whilst the role of insulin in the acute setting
has been the subject of several studies and remains
contentious, the role of insulin in the chronic manage-
ment of diabetes following ACS presentation requires
further exploration.
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LIMITATIONS
This study is a retrospective observational study with
the usual inherent limitations associated with such design
including unmeasured confounding influences. Although
PCI was performed in a single center, the hospital serves
a population of approximately two millions and patients
were referred from seven satellite hospitals. The aim of
the study was to assess outcomes after PCI based on
treatment status for diabetes mellitus. We did not assess
Syntax score as its role in case selection is already recog-
nized and patients accepted for PCI after discussion with
the heart team at our center do not have Syntax score
recorded in the database. The majority of patients with
high Syntax scores (>32) were referred for surgery at the
heart team meeting. We did not collect data on patients
referred for CABG after heart team discussion. Finally,
we did not have any data available on the duration of
DM and the treatment strategies for the glycemic control
prior to the admission.
CONCLUSION
This large observational study of contemporary PCI
practice demonstrates higher post-PCI mortality in dia-
betic patients treated with insulin but not in those
treated with diet or oral hypoglycemics in comparison
to non-diabetic patients. The finding in relation to the
non-insulin treated diabetic population is both novel
and important and in a “real world” population vali-
dates the recommendations of national guidelines to
aggressively control cardiovascular risk factors and to
carefully select cases appropriate for PCI as these
appear to translate to mortality benefits in the popula-
tion with obstructive coronary artery disease undergo-
ing PCI. The challenge in diabetic patients requiring
insulin for glycemic control, however, remains and our
study lends support to outcomes trials in insulin-treated
diabetic patients with proven CAD.
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